Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens
Articolo
Data di Pubblicazione:
2017
Citazione:
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens / Cozzi-lepri, A; Zangerle, R; Machala, L; Zilmer, K; Ristola, M; Pradier, C; Kirk, O; Sambatakou, H; Fätkenheuer, G; Yust, I; Schmid, P; Gottfredsson, M; Khromova, I; Jilich, D; Flisiak, R; Smidt, J; Rozentale, B; Radoi, R; Losso, M. H; Lundgren, J. D; Mocroft, A; Eurosida Study, Group; Castagna, A; Lazzarin, A. - In: HIV MEDICINE. - ISSN 1464-2662. - (2017). [Epub ahead of print] [10.1111/hiv.12557]
Abstract:
There are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Raltegravir; observational treatment comparison; propensity scores; risk of cancer; survival
Elenco autori:
Cozzi-lepri, A; Zangerle, R; Machala, L; Zilmer, K; Ristola, M; Pradier, C; Kirk, O; Sambatakou, H; Fätkenheuer, G; Yust, I; Schmid, P; Gottfredsson, M; Khromova, I; Jilich, D; Flisiak, R; Smidt, J; Rozentale, B; Radoi, R; Losso, M. H; Lundgren, J. D; Mocroft, A; Eurosida Study, Group; Castagna, A; Lazzarin, A
Link alla scheda completa:
Pubblicato in: